This company listing is no longer active
S1BA Stock Overview
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Stealth BioTherapeutics Corp Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.27 |
| 52 Week High | €0.80 |
| 52 Week Low | €0.17 |
| Beta | 1.46 |
| 1 Month Change | -2.90% |
| 3 Month Change | -18.29% |
| 1 Year Change | -67.71% |
| 3 Year Change | -96.03% |
| 5 Year Change | n/a |
| Change since IPO | -97.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| S1BA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.7% | -0.7% | 2.5% |
| 1Y | -67.7% | -21.2% | 5.4% |
Return vs Industry: S1BA underperformed the German Biotechs industry which returned 1.4% over the past year.
Return vs Market: S1BA underperformed the German Market which returned -21.6% over the past year.
Price Volatility
| S1BA volatility | |
|---|---|
| S1BA Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S1BA's share price has been volatile over the past 3 months.
Volatility Over Time: S1BA's weekly volatility has decreased from 20% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 38 | Reenie McCarthy | www.stealthbt.com |
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich’s ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber’s hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company’s product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson’s, Alzheimer’s, Huntington’s, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550.
Stealth BioTherapeutics Corp Fundamentals Summary
| S1BA fundamental statistics | |
|---|---|
| Market cap | €23.54m |
| Earnings (TTM) | -€50.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs S1BA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S1BA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$52.53m |
| Earnings | -US$52.53m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -30.1% |
How did S1BA perform over the long term?
See historical performance and comparison